Group 1: Northern Huachuang (002371) - The company achieved a revenue of 27.301 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 32.97%, and a net profit attributable to shareholders of 5.130 billion yuan, up 14.83% year-on-year [5][6] - In Q3 2025, the company reported a revenue of 11.160 billion yuan, a year-on-year increase of 38.31% and a quarter-on-quarter increase of 40.63%, with a net profit of 1.922 billion yuan, reflecting a year-on-year growth of 14.60% [5][6] - The company focuses on the semiconductor equipment sector, with over 80% of its revenue coming from this area, benefiting from the acceleration of domestic substitution in the semiconductor industry and the expansion of downstream wafer fabs [6][7] - Inventory increased significantly to 30.199 billion yuan, up 30.01% year-on-year, indicating proactive stocking to meet strong market demand and to build a localized, secure supply chain [7] - R&D expenses reached 3.285 billion yuan, a 48.40% increase year-on-year, with a R&D expense ratio of 12.03%, reflecting the company's commitment to innovation and product competitiveness [8] - The company is expected to benefit from the expansion of downstream wafer fab capacities and the domestic substitution trend, with projected revenues of 39.283 billion yuan, 49.665 billion yuan, and 61.156 billion yuan for 2025, 2026, and 2027 respectively [9] Group 2: Zhongsheng Pharmaceutical (002317) - The company reported a revenue of 1.889 billion yuan in the first three quarters of 2025, a slight decrease of 1.01% year-on-year, but a net profit of 251 million yuan, up 68.40% year-on-year [11][12] - In Q3 2025, the company achieved a revenue of 589 million yuan, a year-on-year increase of 8.35%, with a net profit of 63 million yuan, reflecting a year-on-year growth of 2.10% [11] - The R&D pipeline is progressing well, with key products like Anglavi tablets and RAY1225 showing promising clinical advancements, indicating strong potential for market expansion [12] - The company is expected to achieve revenues of 2.841 billion yuan, 3.336 billion yuan, and 3.917 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 307 million yuan, 366 million yuan, and 481 million yuan [13]

[Table_Reportdate] 2025年11月05日 [证券分析师： Table_Authors] 赖菲虹 S0630525050001 lfhong@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20251105 重点推荐 财经要闻 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 晨 会 纪 要 [table_summary] ➢ 1.北方华创（002371）：2025Q3业绩高速增长，平台化布局成效卓著——公司简评报告 ➢ 2.预定利率研究值小幅下调至1.90%，预计短期上限水平保持稳定——保险业态观察（十） ➢ 3.众生药业（002317）：业绩稳健增长，研发进展顺利——公司简评报告 ➢ 4.普门科技（688389）：国际业务增长迅速，静待行业政策影响出清——公司简评报告 ➢ 5.常熟银行（601128）：息差压力缓解，非息收入增长强劲——公司简评报告 ➢ ...

[Table_invest] 买入（维持） 报告原因：业绩点评 [众生药业 Table_NewTitle]（002317）：业绩稳健增长，研 发进展顺利 ——公司简评报告 [Table_Reportdate] 2025年11月04日 [table_main] 投资要点 ➢ 风险提示：销售不及预期风险；市场竞争加剧风险；创新药研发进展不及预期风险。 [盈利预测与估值简表 Table_profits] | | 2022A | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 2,676 | 2,611 | 2,467 | 2,841 | 3,336 | 3,917 | | 增长率（%） | 10.17% | -2.45% | -5.48% | 15.14% | 17.43% | 17.41% | | 归母净利润（百万元） | 322 | 263 | -299 | 307 | 366 | 481 | | 增长率（%） | 16.00% | -18.25% | -213. ...

Investment Rating - The investment rating for the company is "Buy" (首次) [1] Core Views - The company, Zhongsheng Pharmaceutical, has a solid foundation in traditional Chinese medicine and is innovating to drive future growth. The company has established a development strategy focusing on traditional Chinese medicine as the base, innovation as the lead, and specialty as the focus. The product pipeline is rich and diverse, covering major therapeutic areas such as cardiovascular, respiratory, ophthalmology, and digestion [4][14] - The company is expected to see steady growth in its traditional Chinese medicine segment and significant potential from its innovative drug pipeline. The projected net profits for 2025-2027 are estimated at 308 million, 345 million, and 392 million yuan, respectively, with corresponding EPS of 0.36, 0.41, and 0.46 yuan [4][6] Summary by Sections Company Overview - Zhongsheng Pharmaceutical was established in 1979 and officially restructured in 2001, becoming a top 100 pharmaceutical company in China. It focuses on drug research, production, and sales, with key products including the Compound Xue Shuan Tong series, Nao Shuan Tong capsules, and Zhongsheng pills [4][14] Business Structure and Strategy - The company has formed a sustainable business structure with innovative drugs as the leading development driver, traditional Chinese medicine as the business foundation, and chemical generic drugs as beneficial support. The core products are expected to maintain steady growth despite short-term challenges from price reductions due to centralized procurement [5][30] Financial Performance and Forecast - The company's revenue for 2023 was 2,611 million yuan, with a projected increase to 2,802 million yuan in 2025, reflecting a year-on-year growth of 13.5%. The net profit is expected to recover from a loss in 2024 to 308 million yuan in 2025, with a net profit margin of 11% [7][30] - The gross margin for 2024 is projected at 56.1%, with a net margin of 11.0%. The company has effectively controlled its expense ratios, which are expected to further decline as the innovative pipeline matures [7][30] Product Pipeline and Innovation - The innovative drug pipeline focuses on major indications, including COVID-19, influenza, weight loss, and MASH. Key products include the globally first peptide-based 3CL inhibitor for COVID-19, which was conditionally approved in March 2023, and an influenza treatment approved in May 2025 [6][14] - The company has a rich product pipeline that covers various diseases and promotes departmental collaboration, enhancing its competitive edge in the market [32][35] Market Position and Competitive Advantage - The company has established a strong market position with its core products, particularly the Compound Xue Shuan Tong series, which has seen a significant increase in market share due to its clinical evidence and academic promotion efforts [36][38] - The sales of the Compound Xue Shuan Tong capsules are expected to stabilize and grow, benefiting from demographic trends and the increasing demand for chronic disease treatments [36][39]